Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of ASKB589 injection plus CAPOX and a PD-1 inhibitor as first-line therapy for CLDN18.2-positive unresectable advanced gastric/GEJ adenocarcinoma
CTR20233416Phase 3Completed
- Sponsor
- Aosaikang Biotherapeutics
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of ASKB589 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Aosaikang Biotherapeutics. Started Nov 2023; status: completed.
02
Drugs
ASKB589
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20233416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233416.